EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study

Ka-On Lam, Karen Hoi-Lam Li, Roland Ching-Yu Leung, Vikki Tang, Thomas Yau iD

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03077-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Ka-On Lam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Trifluridine, Colorectal Neoplasms, Pyrrolidines, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taiho Pharma Asia Pacific Pte. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Randomized phase III trials showed that using trifluridine/tipiracil (FTD/TPI) in patients with pre-treated metastatic colorectal cancer (mCRC) conferred survival benefit versus placebo. Here, we investigated the effectiveness and safety of FTD/TPI and sought to identify prognostic factors among the mCRC population in Hong Kong. METHODS: A non-interventional, retrospective, multicenter cohort study enrolled patients with mCRC who received FTD/TPI in seven public hospitals in Hong Kong between 2016 and 2020. Overall survival (OS) was the primary endpoint; treatment duration and occurrence of neutropenia were secondary endpoints. We also performed a post hoc analysis to identify factors influencing OS and treatment duration. RESULTS: Overall, 456 patients were included (median age, 64.0 years; 57.5% men). Approximately half (225/456; 49.3%) had RAS wild-type tumors; the median treatment duration was 12.4 weeks (95% confidence interval [CI] 11.1-13.1). Median OS was 7.59 months (95% CI 7.00-8.21). Overall, 289 (63.4%) patients developed neutropenia of any grade and 159 (34.9%) developed grade ≥ 3 neutropenia. Neutropenia at 1 month occurred in 193 (43.1%) patients. The use of granulocyte colony-stimulating factor for neutropenia was reported for 42 (9.2%) patients. The development of neutropenia, absolute neutrophil count decrease of ≥ 2 grades in 1 month, absence of liver metastasis, and RAS wild-type status were associated with significantly longer OS and, except for RAS wild-type status (not analyzed), longer treatment duration (p < 0.05 for all comparisons). CONCLUSION: Our data show that treatment with FTD/TPI offers survival benefits in patients with refractory mCRC in Hong Kong consistent with randomized controlled trials and other real-world studies. Furthermore, the prognosis in patients receiving FTD/TPI appears to be significantly better in those who develop neutropenia, with RAS wild-type status, or those without liver metastases, despite a higher rate of dose reduction in the real-world setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrifluridineColorectal NeoplasmsPyrrolidinesAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedFemaleHong KongAgedRetrospective StudiesDrug CombinationsThymineNeoplasm MetastasisNeutropeniaAdult

Stichwörter der Autor:innen

FTD/TPIMetastatic colorectal cancerNeutropeniaPrognostic factorReal-worldTAS-102Trifluridine/tipiracil

Substanzen

Trifluridinetrifluridine tipiracil drug combinationPyrrolidinesDrug CombinationsThymine

Autor:innen und Institutionen

  • Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
  • Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
  • Centre of Cancer Medicine and University Department of Medicine, The University of Hong Kong, Hong Kong SAR, China. tyaucc@hku.hk.

ORCID-Profile: Thomas Yau

Förderung

  • Taiho Pharma Asia Pacific Pte. Ltd.

Zitieren

APA

Lam, K. O., Li, K. H., Leung, R. C., Tang, V., & Yau, T. (2025). Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-03077-4

Vancouver

Lam KO, Li KH, Leung RC, Tang V, Yau T. Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study. Advances in Therapy. 2025. doi:10.1007/s12325-024-03077-4

BibTeX
@article{Lam2025,
  author = {Lam, Ka-On and Li, Karen Hoi-Lam and Leung, Roland Ching-Yu and Tang, Vikki and Yau, Thomas},
  title = {Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03077-4}
}
Kostenlos starten →